123 related articles for article (PubMed ID: 37062281)
1. Survival-Adjusted FEV1 and BMI Percentiles for Patients with Cystic Fibrosis before the Era of Triple CFTR Modulator Therapy in Germany.
Dittrich AS; Dumke M; Kapl F; Schneider P; Wege S; Gräber S; Stahl M; Herth FJ; Naehrlich L; Mall MA; Sommerburg O;
Respiration; 2023; 102(5):1. PubMed ID: 37062281
[TBL] [Abstract][Full Text] [Related]
2. Early-Life Height Attainment in Cystic Fibrosis Is Associated with Pulmonary Function at Age 6 Years.
Sanders DB; Slaven JE; Maguiness K; Chmiel JF; Ren CL
Ann Am Thorac Soc; 2021 Aug; 18(8):1335-1342. PubMed ID: 33476226
[No Abstract] [Full Text] [Related]
3. Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years.
Sanders DB; Fink A; Mayer-Hamblett N; Schechter MS; Sawicki GS; Rosenfeld M; Flume PA; Morgan WJ
J Pediatr; 2015 Nov; 167(5):1081-8.e1. PubMed ID: 26340874
[TBL] [Abstract][Full Text] [Related]
4. Reference percentiles of FEV1 for the Canadian cystic fibrosis population: comparisons across time and countries.
Kim SO; Corey M; Stephenson AL; Strug LJ
Thorax; 2018 May; 73(5):446-450. PubMed ID: 29434047
[TBL] [Abstract][Full Text] [Related]
5. Disease-specific reference equations for lung function in patients with cystic fibrosis.
Kulich M; Rosenfeld M; Campbell J; Kronmal R; Gibson RL; Goss CH; Ramsey B
Am J Respir Crit Care Med; 2005 Oct; 172(7):885-91. PubMed ID: 15976373
[TBL] [Abstract][Full Text] [Related]
6. Reference percentiles for FEV(1) and BMI in European children and adults with cystic fibrosis.
Boëlle PY; Viviani L; Busson PF; Olesen HV; Ravilly S; Stern M; Assael BM; Barreto C; Drevinek P; Thomas M; Krivec U; Mei-Zahav M; Vibert JF; Clement A; Mehta A; Corvol H; ;
Orphanet J Rare Dis; 2012 Sep; 7():64. PubMed ID: 22958330
[TBL] [Abstract][Full Text] [Related]
7. Current Management of Patients with RPE65 Mutation Associated Inherited Retinal Degenerations in Europe: Results of a 2-Year Follow-Up Multinational Survey.
Lorenz B; Tavares J; van den Born LI; Marques JP; Pilotto E; Stingl K; Charbel Issa P; Leroux D; Dollfus H; Scholl HPN
Ophthalmic Res; 2023; 66(1):727-748. PubMed ID: 36878196
[TBL] [Abstract][Full Text] [Related]
8. [Italian Cystic Fibrosis Registry (ICFR). Report 2015-2016].
Giordani B; Amato A; Majo F; Ferrari G; Quattrucci S; Minicucci L; Padoan R; Floridia G; Salvatore D; Carnovale V; Puppo Fornaro G; Taruscio D; Salvatore M;
Epidemiol Prev; 2019; 43(4S1):1-36. PubMed ID: 31370382
[TBL] [Abstract][Full Text] [Related]
9. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
[TBL] [Abstract][Full Text] [Related]
10. [Italian Cystic Fibrosis Registry (ICFR). Report 2017-2018].
Campagna G; Amato A; Majo F; Ferrari G; Quattrucci S; Padoan R; Floridia G; Salvatore D; Carnovale V; Puppo Fornaro G; Taruscio D; Salvatore M;
Epidemiol Prev; 2021; 45(3 Suppl 1):1-37. PubMed ID: 34132083
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal Trends in Real-World Outcomes after Initiation of Ivacaftor. A Cohort Study from the Cystic Fibrosis Registry of Ireland.
Kirwan L; Fletcher G; Harrington M; Jeleniewska P; Zhou S; Casserly B; Gallagher CG; Greally P; Gunaratnam C; Herzig M; Linnane B; McElvaney NG; McKone EF; McNally P; Mullane D; Ní Chróinín M; O'Mahony M; Plant BJ; Jackson AD
Ann Am Thorac Soc; 2019 Feb; 16(2):209-216. PubMed ID: 30427731
[TBL] [Abstract][Full Text] [Related]
12. Analysis of a large cohort of cystic fibrosis patients with severe liver disease indicates lung function decline does not significantly differ from that of the general cystic fibrosis population.
Polineni D; Piccorelli AV; Hannah WB; Dalrymple SN; Pace RG; Durie PR; Ling SC; Knowles MR; Stonebraker JR
PLoS One; 2018; 13(10):e0205257. PubMed ID: 30307979
[TBL] [Abstract][Full Text] [Related]
13. [Italian Cystic Fibrosis Register - Report 2010].
Amato A; Ferrigno L; Salvatore M; Toccaceli V;
Epidemiol Prev; 2016; 40(2 Suppl 2):1-47. PubMed ID: 27291389
[TBL] [Abstract][Full Text] [Related]
14. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.
Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET
Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367
[TBL] [Abstract][Full Text] [Related]
15. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
[TBL] [Abstract][Full Text] [Related]
16. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Heneghan M; Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD010966. PubMed ID: 37983082
[TBL] [Abstract][Full Text] [Related]
17. [Italian Cystic Fibrosis Registry (ICFR). Report 2019-2020].
Campagna G; Amato A; Majo F; Ferrari G; Quattrucci S; Padoan R; Floridia G; Salvatore D; Carnovale V; Puppo Fornaro G; Taruscio D; Salvatore M;
Epidemiol Prev; 2022; 46(4 Suppl 2):1-38. PubMed ID: 36102313
[TBL] [Abstract][Full Text] [Related]
18. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with pubertal growth outcomes in cystic fibrosis: Early Growth and Puberty in CF.
Patil R; Magaret AS; Jain R; Taylor-Cousar J; Hughan KS; Kazmerski TM
J Cyst Fibros; 2024 May; 23(3):538-544. PubMed ID: 37981481
[TBL] [Abstract][Full Text] [Related]
20. Bone accrual and structural changes over one year in youth with cystic fibrosis.
Bass RM; Zemel BS; Stallings VA; Leonard MB; Tsao J; Kelly A
J Clin Transl Endocrinol; 2022 Jun; 28():100297. PubMed ID: 35433270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
